Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 6.1% After Insider Selling

by · The Cerbat Gem

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price was down 6.1% during trading on Tuesday following insider selling activity. The stock traded as low as $16.65 and last traded at $16.8450. Approximately 448,966 shares traded hands during mid-day trading, a decline of 1% from the average daily volume of 454,036 shares. The stock had previously closed at $17.93.

Specifically, insider Joseph P. Lyssikatos sold 5,000 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $16.84, for a total transaction of $84,200.00. Following the sale, the insider directly owned 897,688 shares of the company’s stock, valued at approximately $15,117,065.92. This represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Analysts Set New Price Targets

A number of research analysts have recently commented on ELVN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $41.00.

Read Our Latest Stock Analysis on ELVN

Enliven Therapeutics Stock Up 1.2%

The company has a market cap of $993.17 million, a P/E ratio of -9.10 and a beta of 0.35. The business has a fifty day moving average price of $20.18 and a 200-day moving average price of $20.30.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. As a group, research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in shares of Enliven Therapeutics during the first quarter worth approximately $60,000. BNP Paribas Financial Markets increased its holdings in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the period. AlphaQuest LLC bought a new stake in Enliven Therapeutics during the third quarter worth $96,000. Tower Research Capital LLC TRC boosted its holdings in shares of Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after purchasing an additional 3,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS grew its position in Enliven Therapeutics by 58.1% in the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after acquiring an additional 2,500 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

Further Reading